Navigation Links
Liraglutide provides significantly better glucose control than,insulin glargine in phase 3 study

COPENHAGEN, June 21, 2007-Novo Nordisk today announced clinical results from the first of five phase 3 studies with liraglutide - the once-daily human GLP-1 analogue. The 26-week study is part of the LEAD(TM) (Liraglutide Effect and Action in Diabetes) programme and included 581 patients with type 2 diabetes inadequately controlled by two of the most widely used oral antidiabetic drugs: metformin and a sulfonylurea (glimepiride). All patients in the study continued the two oral drugs and were randomised to add one daily injection of liraglutide, placebo or insulin glargine.

The average HbA1c level at the beginning of the study was between 8.0% and 8.5% and at the end of the study, more than 50% of patients in the liraglutide group had reached the American Diabetes Association goal of HbA1c < 7%. Furthermore, more than 35% achieved the American Association of Clinical Endocrinologists HbA1c target of <= 6.5%. The HbA1c reduction achieved in the liraglutide group was more than 0.2 percentage points better than in the insulin glargine group, a difference which is statistically significant.

The average weight of the patients at the beginning of the study was approximately 85 kg. At the end of the study, the difference in body weight between the liraglutide and insulin glargine treatment groups was on average 3.5 kg, statistically significant in favour of liraglutide.

Liraglutide in combination with metformin and glimepiride was well tolerated. The most frequently reported adverse event in the liraglutide arm was nausea at an absolute level of between 10 and 15%. As expected, the combination of a GLP-1 analogue with a sulfonylurea leads to some of the patients experiencing hypoglycaemia. The overall hypoglycaemia event rate in the liraglutide and insulin glargine groups was not significantly different.

Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk, said: "We are very
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
2. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
3. Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients
4. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
5. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial
6. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
7. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
8. 2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion
Post Your Comments:
(Date:1/23/2015)... , Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... personalized immune therapies for operable and inoperable solid tumor cancers, ... at the 7 th Annual Phacilitate Immunotherapy Forum in ... presentation at Phacilitate will take place on January 26 at ...
(Date:1/23/2015)... 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is ... Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... fiduciary duties to shareholders. On January 21, ... reporting that Advaxis had misrepresented the clinical data for ...
(Date:1/23/2015)... Fla. , Jan. 23, 2015  iMD Companies, Inc. (ICBU) ... to increase market share and grab a foothold in the ... influence, production capabilities and a presence in the sector, and ... facilitate the growth of hemp and medical marijuana, iMD is ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... N.C., June 30, 2011 AAIPharma Services Corp., a ... announced that it has passed inspection of its Durham ... with no inspectional observations. The May 2011 audit is ... have not been issued an FDA-483 citing any inspection ...
... 2011 Metamark Genetics, a privately-held oncology molecular ... Intelligence™ company, today announced a development and commercialization ... multiplex protein detection platform with image analysis technology ... and predictive assays for early-stage cancers. ...
Cached Medicine Technology:AAIPharma Services Builds Compliance Record at Lab, Manufacturing and Packaging Operations 2Metamark Genetics Partners with Definiens on Tissue-Based Cancer Diagnostics 2Metamark Genetics Partners with Definiens on Tissue-Based Cancer Diagnostics 3
(Date:1/22/2015)... 22, 2015 Blue Cross and Blue Shield ... exemplify what it means to “Live Fearless.” , ... to share their stories about how they or someone they ... others by living in the moment. By telling these types ...
(Date:1/22/2015)... January 22, 2015 Thousand of GranuFlo ... Care recalled its GranuFlo and NaturaLyte dialysis concentrates continue ... in U.S. District Court, District of Massachusetts, Bernstein Liebhard ... the Court has remanded a case filed by the ...
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
(Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
(Date:1/22/2015)... has released a new blog post explaining the importance of keeping ... costs of an auto insurance policy . , Clients who ... for their vehicle insurance policies. The safety a vehicle offers from ... Because of this, drivers should always carry a first aid kit ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... Well Woman Centre of Ireland has warned that outsourcing ... some patients. It could also lead to lead to inconsistencies ... ,The Well Woman Centre has criticized the Health ... US, as it could have serious ramifications for women with ...
... PET-CT scanners with standard commercial software designed to provide ... disease in as many as 40 percent of patients ... professor in the Division of Cardiology at The University ... the abnormalities upon his initial use of cardiac PET-CT ...
... the development and commercialization of proprietary pharmaceuticals for ... , today announced that under the Special Protocol ... the United States Food and Drug Administration (FDA) ... for crofelemer for the treatment of chronic diarrhea ...
... the rage today in advanced countries. But consumers seeking ... questions before they decide to go in for ... functional foods market is a $40 billion industry. ... lower bad cholesterol (LDL). ,* Probiotic yoghurts ...
... the University of Southern California have applied a nanoscale ... up an old puzzle of the global carbon and ... advanced online publication of The ISME Journal. ... nanometer-scale, secondary ion mass spectrometry) located at Lawrence Livermore ...
... get hookah smoking exempted from Englands smoking ban for ... health effects , doctors writing in this weeks BMJ ... ,A hookah is a glass based waterpipe used for ... smoking herbal fruits after meals, but it is becoming ...
Cached Medicine News:Health News:Irish Outsourcing of Smear Test may Result in Cervical Cancer Being Undetected 2Health News:Inaccuracies in Cardiac PET-CT Scanning 2Health News:Inaccuracies in Cardiac PET-CT Scanning 3Health News:Napo Obtains Special Protocol Assessment Agreement From FDA for Crofelemer 2Health News:Functional Food What is That, Ask First 2Health News:Functional Food What is That, Ask First 3Health News:Nanospectrometer Aids in Identifying Nutrient Cycle 2Health News:Ban on Hookah Smoking Should Stay, Argue Doctors 2
... The Minimally Invasive Hip Instruments ... THA through a mini-incision using ... set of instruments helps reduce ... invasive THA by optimizing exposure ...
The Endotrac™ System includes an Obturator, Slotted Cannula, Synovial Elevator, Ligament Probe, Ligament Rasp, Blade Handle, two Retractors and sterilizable tray. The Endotrac&trade....
Instrument set for carpal tunnel release....
Standard arthroscopy graspers for small joints. Also available are Mosquito Tip Graspers, 45 degree Forceps, SquareTrimmer Blunt Tip Forceps and SST Scoop Tip Forceps....
Medicine Products: